Discovery of 95 PTSD loci provides insight into genetic architecture and neurobiology of trauma and stress-related disorders

Competing Interest Statement

L.J.B. is listed as an inventor on Issued U.S. Patent 8,080,371, "Markers for Addiction" covering the use of certain SNPs in determining the diagnosis, prognosis, and treatment of addiction. C.-Y.C. and H.R. are employees of Biogen. A.M.D. holds equity in CorTechs Labs, Inc., and serves on the Scientific Advisory Board of Human Longevity, Inc., and the Mohn Medical Imaging and Visualization Centre; A.M.D. receives funding through research grants with General Electric Healthcare. C.F. was a speaker for Janssen in 2021. I.B.H. is the Co-Director, Health and Policy at the Brain and Mind Centre (BMC) University of Sydney; the BMC operates an early-intervention youth services at Camperdown under contract to headspace. I.B.H. is the Chief Scientific Advisor to, and a 3.2% equity shareholder in, InnoWell Pty Ltd; InnoWell was formed by the University of Sydney (45% equity) and PwC (Australia; 45% equity) to deliver the $30 M Australian Government-funded Project Synergy. H.H. received consultancy fees from Ono Pharmaceutical and honorarium from Xian Janssen Pharmaceutical. In the past 3 years, R.C.K. was a consultant for Cambridge Health Alliance, Canandaigua VA Medical Center, Holmusk, Partners Healthcare, Inc., RallyPoint Networks, Inc., and Sage Therapeutics. He has stock options in Cerebral Inc., Mirah, PYM, Roga Sciences and Verisense Health. L.A.M.L. reports spousal IP payments from Vanderbilt University for technology licensed to Acadia Pharmaceuticals unrelated to the present work. C.M. has served on advisory boards of Receptor Life Sciences, Otsuka Pharmaceuticals and Roche Products Limited and has received support from National Institute on Alcohol Abuse and Alcoholism, National Institute of Mental Health, Department of Defense- CDMRP * US Army Research Office * DARPA, Bank of America Foundation, Brockman Foundation, Cohen Veterans Bioscience, Cohen Veterans Network, McCormick Foundation, Home Depot Foundation, New York City Council, New York State Health, Mother Cabrini Foundation, Tilray Pharmaceuticals, and Ananda Scientific. P.M.P. received payment or honoraria for lectures and presentations in educational events for Sandoz, Daiichi Sankyo, Eurofarma, Abbot, Libbs, Instituto Israelita de Pesquisa e Ensino Albert Einstein, Instituto D'Or de Pesquisa e Ensino. R.P. paid for his editorial work on the journal Complex Psychiatry and received a research grant outside the scope of this study from Alkermes. J.W.S. is a member of the Scientific Advisory Board of Sensorium Therapeutics (with equity), and has received grant support from Biogen, Inc.; J.W.S. is PI of a collaborative study of the genetics of depression and bipolar disorder sponsored by 23andMe for which 23andMe provides analysis time as in-kind support but no payments. M.B.S. has in the past 3 years received consulting income from Acadia Pharmaceuticals, Aptinyx, atai Life Sciences, BigHealth, Biogen, Bionomics, BioXcel Therapeutics, Boehringer Ingelheim, Clexio, Eisai, EmpowerPharm, Engrail Therapeutics, Janssen, Jazz Pharmaceuticals, NeuroTrauma Sciences, PureTech Health, Sage Therapeutics, Sumitomo Pharma, and Roche/Genentech. M.B.S. has stock options in Oxeia Biopharmaceuticals and EpiVario. M.B.S. has been paid for his editorial work on Depression and Anxiety (Editor-in-Chief), Biological Psychiatry (Deputy Editor), and UpToDate (Co-Editor-in-Chief for Psychiatry). M.B.S. has also received research support from NIH, Department of Veterans Affairs, and the Department of Defense. M.B.S. is on the scientific advisory board for the Brain and Behavior Research Foundation and the Anxiety and Depression Association of America. In the past 3 years, D.J.S. has received consultancy honoraria from Discovery Vitality, Johnson & Johnson, Kanna, L'Oreal, Lundbeck, Orion, Sanofi, Servier, Takeda and Vistagen. MLK reports unpaid membership on the Scientific Committee for the ISSTD.

Funding Statement

Major financial support for the PTSD-PGC was provided by the Cohen Veterans Bioscience, Stanley Center for Psychiatric Research at the Broad Institute, and the National Institute of Mental Health (NIMH; R01MH106595, R01MH124847, R01MH124851).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

IRB of University of California San Diego gave ethical approval for this work

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes